Cumberland Pharmaceuticals (CPIX) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Organigram Global (OGI) over the past year, gaining 193.5% versus a loss of 60.6%. Over five years, CPIX leads with a +161.9% price change compared with -93.3% for OGI. Cumberland Pharmaceuticals is the larger company by market cap ($87.6 million vs $82.3 million), about 1.1 times the size.
On valuation, Organigram Global trades at a lower forward P/E (27.8x vs 41.7x for Cumberland Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | OGI |
|---|---|---|
| Share price | $5.84 | $0.583 |
| Market cap | $87.57M | $82.27M |
| 1-day change | -7.30% | -7.40% |
| YTD return | +46.73% | -65.30% |
| 1-year return | +193.47% | -60.61% |
| 5-year return | +161.88% | -93.25% |
| P/E ratio (TTM) | — | 1.36 |
| Forward P/E | 41.71 | 27.76 |
| EPS (TTM) | $-0.57 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.52M | — |
| Revenue growth (YoY) | +17.57% | — |
| Net income (latest FY) | $-2.84M | — |
| Gross margin | 85.02% | — |
| Operating margin | -6.27% | — |
| Net margin | -6.37% | — |
| 52-week high | $9.28 | $2.24 |
| 52-week low | $2.00 | $0.583 |
| Distance from 52-week high | -37.07% | -73.97% |
| Analyst consensus | — | strong_buy |
| Average volume | 114.52K | 567.77K |
| Shares outstanding | 15.00M | 141.11M |
| Employees | 88 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed OGI by 254.1 percentage points over the past year.
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
CPIX vs OGI FAQ
Which is bigger, Cumberland Pharmaceuticals or Organigram Global?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $87.57M compared with $82.27M for Organigram Global (OGI).
Which stock has performed better over the past year, CPIX or OGI?
CPIX returned +193.47% over the past 12 months, compared with -60.61% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.